Intellia Therapeutics, Inc. ($NTLA) Stock Forecast: Up 5.1% Today

What is Intellia Therapeutics, Inc.?

Intellia Therapeutics (NTLA) is a leading clinical-stage gene editing company known for its focus on CRISPR-based therapies, aiming to transform the field of medicine. The stock displayed a notable bullish trend today.

Why is Intellia Therapeutics, Inc. going up?

NTLA stock is up 5.1% on Oct 9, 2025 14:50

• NTLA experienced a significant increase of 19.7% in its shares, accompanied by above-average trading volume.
• Analysts from Wall Street are optimistic about NTLA, projecting a potential upside of 63.7% for the stock, reflecting favorable market sentiment.
• Recent changes in earnings estimates for Intellia Therapeutics may have contributed to the price surge, hinting at further growth in the short term.
• The company disclosed the provision of inducement grants under Nasdaq Listing Rule 5635 (c)(4), potentially enhancing investor confidence in the company's future prospects.

NTLA Price Chart

NTLA Technical Analysis

NTLA News

Intellia Therapeutics ( NTLA ) Soars 19.7%: Is Further Upside Left in the Stock?

Intellia Therapeutics (NTLA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

https://www.zacks.com/stock/news/2765293/intellia-therapeutics-ntla-soars-197-is-further-upside-left-in-the-stock

Wall Street Analysts Predict a 63.7% Upside in Intellia Therapeutics ( NTLA ) : Here's What You Should Know

The consensus price target hints at a 63.7% upside potential for Intellia Therapeutics (NTLA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

https://www.zacks.com/stock/news/2764539/wall-street-analysts-predict-a-637-upside-in-intellia-therapeutics-ntla-heres-what-you-should-know

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )

CAMBRIDGE, Mass., Oct. 03, 2025 ( GLOBE NEWSWIRE ) -- Intellia Therapeutics, Inc. ( NASDAQ:NTLA ) , a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that on October 1, 2025, it awarded inducement grants to six new ...

https://www.globenewswire.com/news-release/2025/10/03/3161199/0/en/Intellia-Therapeutics-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html

Trending Today

Beyond Meat Inc. ($BYND) Stock Forecast: Down 5.9% Today

Cleveland-Cliffs Inc. ($CLF) Stock Forecast: Down 5.3% Today

Solana ($SOL) Crypto Forecast: Up 5.3% Today

XRP ($XRP) Crypto Forecast: Up 5.2% Today

Ethereum ($ETH) Crypto Forecast: Up 5.1% Today

Pepe ($PEPE) Crypto Forecast: Up 6.3% Today

Cardano ($ADA) Crypto Forecast: Up 5.0% Today

Dogecoin ($DOGE) Crypto Forecast: Up 5.5% Today

ZCash ($ZEC) Crypto Forecast: Up 6.6% Today

Bittensor ($TAO) Crypto Forecast: Up 5.4% Today

Intellia Therapeutics, Inc. Price History

18.08.2025 - NTLA Stock was up 25.5%

• The surge in Intellia Therapeutics' stock price followed the completion of Phase 3 enrollment for its HAELO trial ahead of schedule, demonstrating progress in its pipeline development.
• Investor optimism and confidence were likely enhanced by the anticipation of Phase 3 topline data, expected in the first half of 2026.
• The bullish movement in Intellia's stock was influenced by positive market sentiment, with major indices like the Nasdaq Composite gaining over 200 points, reflecting increased interest in growth stocks in the biotech sector.

22.08.2025 - NTLA Stock was up 5.8%

• The stock of NTLA showed a strong bullish movement today.
• The completion of enrollment in the pivotal phase III HAELO study on lonvo-z for hereditary angioedema led to a nearly 30% surge in Intellia shares.
• Positive longer-term data from the ongoing Phase 1 clinical trial of Nexiguran Ziclumeran for the treatment of Hereditary Transthyretin Amyloidosis with Polyneuropathy also increased investor confidence.
• The expectation of Phase 3 topline data in the first half of 2026 further added to the positive sentiment surrounding Intellia Therapeutics.

08.09.2025 - NTLA Stock was up 25.1%

• Analysts on Wall Street foresee a 63.7% upside potential for NTLA, reflecting favorable sentiment towards the stock.
• The company disclosed inducement grants in line with Nasdaq Listing Rule 5635, highlighting efforts to attract top talent and foster innovation.
• The rising trend in earnings estimate revisions may have contributed to the stock's bullish performance.
• Overall, positive developments and optimistic analyst projections appear to have propelled the strong bullish trend in Intellia Therapeutics' stock today.

09.09.2025 - NTLA Stock was up 5.1%

• NTLA experienced a significant increase of 19.7% in its shares, accompanied by above-average trading volume.
• Analysts from Wall Street are optimistic about NTLA, projecting a potential upside of 63.7% for the stock, reflecting favorable market sentiment.
• Recent changes in earnings estimates for Intellia Therapeutics may have contributed to the price surge, hinting at further growth in the short term.
• The company disclosed the provision of inducement grants under Nasdaq Listing Rule 5635 (c)(4), potentially enhancing investor confidence in the company's future prospects.

25.08.2025 - NTLA Stock was down 5.3%

• Despite positive progress on key clinical studies, the market response may have been dampened by the absence of immediate revenue-generating activities or commercialization opportunities.
• Investors could be capitalizing on recent stock price gains following a successful enrollment completion in a pivotal study for lonvo-z in hereditary angioedema.
• Concerns surrounding the timeline for Phase 3 data release in 2026 might have contributed to a shift in market sentiment, prompting a sell-off of the stock.
• The general downward trend could also be a result of broader market conditions or sector rotations affecting biotech stocks, leading traders to reassess their positions in NTLA.

07.09.2025 - NTLA Stock was down 5.4%

• The drop in NTLA stock could be a result of investors taking profits following a recent increase in the stock's value.
• Concerns among investors about the potential dilution of current shares due to the announcement of inducement grants may have triggered a sell-off.
• Investors could be reexamining their positions in NTLA stock due to apprehensions about competition within the gene editing industry.

08.07.2025 - NTLA Stock was down 5.1%

• NTLA reported a narrower Q2 loss and exceeded revenue predictions, yet the stock faced a bearish movement.
• The market's negative response could stem from apprehensions regarding the company's future growth or guidance.
• Investors might be selling to secure profits after a recent stock price surge driven by encouraging pipeline updates.
• Despite the earnings beat and advancements in phase III studies for ATTR and HAE programs, broader market conditions or sector shifts may be casting a shadow.

19.08.2025 - NTLA Stock was up 11.0%

• Intellia Therapeutics (NTLA) witnessed a substantial 29.8% surge in its stock price.
• The Phase 3 HAELO trial enrollment completion ahead of schedule and the expected release of Phase 3 topline data in the first half of 2026 were factors contributing to the positive momentum.
• The optimistic trend in earnings estimate revisions also bolstered the stock's upward trajectory.
• In conclusion, Intellia Therapeutics' impressive performance was fueled by advancements in its clinical trials and positive market outlook towards the biotechnology industry.

16.08.2025 - NTLA Stock was up 5.8%

• Factors contributing to the upward trend in NTLA include:
• Favorable market feelings towards biotech firms
• Possible breakthroughs or progress in CRISPR technology
• Speculation or expectation of future positive events or advancements within the company

22.07.2025 - NTLA Stock was up 5.4%

• NTLA experienced a strong bullish movement possibly due to positive developments in the biotechnology sector.
• Cathie Wood's Ark Invest selling off shares of Robinhood and Shopify may have redirected investor interest towards other innovative companies like Intellia Therapeutics.
• The hype surrounding AI launches could have also contributed to increased investor confidence in NTLA's gene editing technologies.
• Overall, the bullish movement in NTLA could be a result of shifting investor focus towards promising biotech companies amidst market uncertainties.

19.07.2025 - NTLA Stock was down 6.4%

• The decline in NTLA's stock today could be attributed to investors taking profits following a period of strong growth.
• While news of CRISPR Therapeutics' increasing Casgevy sales was well-received, investors might have been underwhelmed by NTLA's financial performance or future prospects.
• Market fluctuations and sector shifts may have also influenced NTLA's stock decline, as investors may be seeking out other appealing opportunities within the biotech industry.

18.08.2025 - NTLA Stock was up 14.7%

• Intellia Therapeutics Inc. (NTLA) experienced a strong bullish movement today.
• The overall bullish sentiment in the market, with the Nasdaq Composite gaining over 200 points, likely contributed to the positive movement in NTLA.
• The acquisition announcement by Radian Group Inc. (RDN) for $1.7 billion may have also boosted investor confidence in the biotechnology sector, including companies like Intellia Therapeutics Inc.
• The positive market momentum and the acquisition news could have created a favorable environment for NTLA, leading to its strong bullish movement today.